文章：

德国引入化学免疫疗法前后慢性淋巴细胞白血病患者生存情况

Survival of patients with chronic lymphocytic leukemia before and after the introduction of chemoimmunotherapy in Germany

原文发布日期：2021-10-29

DOI: 10.1038/s41408-021-00556-7

类型: Article

开放获取: 是

英文摘要：

Chronic lymphocytic leukemia (CLL) is the most common leukemia of adults in western countries. Therapy is indicated in symptomatic and advanced stages and has changed fundamentally since 2010 when rituximab, an anti-CD20 antibody, has been approved for treatment of CLL. Until then therapy had been based on chemotherapy drugs. This study investigates whether survival in CLL patients improved at the population level after the introduction of combined chemoimmunotherapy. Data from the cancer registry North-Rhine Westphalia was used to calculate relative survival (RS) by applying period analyses. Age-standardized 5-year RS increased from 79% in 1998–2002 (75% in 2003–2007) to 81% in the calendar period 2008–2012 and 88% in 2013–2016 for men and continuously from 71% in 1998–2002 to 92% in 2013–2016 for women. In CLL patients aged 15–69 years 5-year RS increased from 83% to 90% for men and from 82% to 94% for women after adding an anti-CD20-antibody to chemotherapy while in the older age group of 70–79-year-old CLL patients an increase by 20 percentage points was observed. These findings show marked improvements in the survival of CLL patients at the population level subsequently to the approval of anti-CD 20 antibodies like rituximab, ofatumumab or obinutuzumab for CLL treatment.
 

摘要翻译： 

慢性淋巴细胞白血病（CLL）是西方国家成年人中最常见的白血病。针对有症状及晚期患者的治疗自2010年起发生根本性变革，当时抗CD20抗体利妥昔单抗获准用于CLL治疗，此前疗法主要依赖于化疗药物。本研究旨在探究联合化学免疫疗法问世后，CLL患者的群体生存率是否得到改善。通过运用时段分析法对北莱茵-威斯特法伦州癌症登记处的数据进行分析，计算得出相对生存率（RS）。男性年龄标准化5年相对生存率从1998-2002年的79%（2003-2007年为75%）上升至2008-2012年间的81%，2013-2016年间达到88%；女性则从1998-2002年的71%持续增长至2013-2016年的92%。在15-69岁年龄段的CLL患者中，化疗联合抗CD20抗体治疗后，男性5年相对生存率从83%提升至90%，女性从82%升至94%；而在70-79岁高龄患者群体中，该数值增长了20个百分点。这些研究结果表明，自利妥昔单抗、奥法木单抗或奥滨尤妥珠单抗等抗CD20抗体获准用于CLL治疗后，患者群体生存率获得显著提升。

原文链接：

Survival of patients with chronic lymphocytic leukemia before and after the introduction of chemoimmunotherapy in Germany